oh yeah - well Jefferies dropped their PT on Aveo to $6. Comments below:
The firm comments, "AVEO shared new details of the final overall survival (OS) analysis for tivozanib from its Phase 3 first-line kidney cancer study. We are incrementally more cautious following these data, particularly new subgroup analyses of the OS data, which we thought would be supportive but are instead mixed. We remain concerned about both the regulatory and commercial prospects for tivo."